Stockscreener 앱 받기
17.18
2.51%
0.42
전일 마감가:
$16.76
열려 있는:
$17.04
하루 거래량:
318.54K
Relative Volume:
1.68
시가총액:
$599.45M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+1.66%
1개월 성능:
-8.96%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$16.80
$18.10
1주일 범위
$15.40
$18.15
52주 변동 폭
$15.40
$25.58
First Tracks Biotherapeutics Inc Stock (TRAX) Company Profile
명칭
First Tracks Biotherapeutics Inc
전화
212-373-3000
주소
10770 WATERIDGE CIRCLE, SAN DIEGO
Compare TRAX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRAX
First Tracks Biotherapeutics Inc
|
17.18 | 584.80M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
First Tracks Biotherapeutics Inc Stock (TRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 개시 | Leerink Partners | Outperform |
| 2026-04-24 | 개시 | Wedbush | Outperform |
| 2026-04-23 | 개시 | JP Morgan | Overweight |
| 2026-04-22 | 개시 | Barclays | Overweight |
| 2026-04-21 | 개시 | UBS | Buy |
First Tracks Biotherapeutics Inc 주식(TRAX)의 최신 뉴스
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences - Sahm
Zumiez Inc. to Report Fiscal 2026 First Quarter Results - The Manila Times
First Tracks Biotherapeutics (TRAX) Stock Forecast and Price Target 2026 $TRAX - MarketBeat
TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
First Tracks Biotherapeutics, Inc.Ordinary Shares (NQ: TRAX - FinancialContent
AnaptysBio (ANAB) Valuation After Spin Off And Shift To Royalty Focused Model - Sahm
First Tracks Biotherapeutics (NASDAQ: TRAX) registers 10.5M resale shares; issuer gets no proceeds - Stock Titan
Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway - TipRanks
TRAX SEC FilingsFirst Tracks Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Form 424B3 First Tracks Biotherapeu - StreetInsider
First Tracks Biotherapeutics (NASDAQ: TRAX) registers 10.5M resale shares - Stock Titan
First Tracks Biotherapeutics 1Q 2026: Net loss $(50.5M), Revenue $0— 10-Q Summary - TradingView
[Form 4] First Tracks Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
First Tracks Biotherapeutics (NASDAQ: TRAX) details Q1 loss and major post spin-off cash raises - Stock Titan
First Tracks Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
[8-K] First Tracks Biotherapeutics, Inc. Reports Material Event - Stock Titan
Director at First Tracks Bio (NASDAQ: TRAX) receives new equity awards - Stock Titan
Director Magda Marquet granted options and RSUs at First Tracks (TRAX) - Stock Titan
Director at First Tracks Biotherapeutics (TRAX) granted options and RSUs - Stock Titan
Director John A. Orwin receives new equity awards at First Tracks Biotherapeutics (TRAX) - Stock Titan
First Tracks (TRAX) awards director 42,000 options and 15,000 RSUs - Stock Titan
Executive equity awards at First Tracks Biotherapeutics (TRAX) detailed - Stock Titan
First Tracks (TRAX) CEO receives new stock options and RSU awards - Stock Titan
First Tracks Biotherapeutics (TRAX) CFO receives new option and RSU awards - Stock Titan
First Tracks Biotherapeutics, Inc. (TRAX) Cash From Financing (TTM) - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Dividend (TTM) - Zacks Investment Research
This First Tracks Biotherapeutics analyst begins coverage on a bullish note; here are top 4 initiations for Monday - MSN
[EFFECT] First Tracks Biotherapeutics, Inc. SEC Filing - Stock Titan
Is AnaptysBio (ANAB) 51.9% Undervalued After Q1 2026 EPS/Revenue - GuruFocus
TRAX Should I Buy - Intellectia AI
AnaptysBio (NASDAQ: ANAB) shifts to royalty focus after Q1 2026 loss - Stock Titan
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
First Tracks Biotherapeutics, Inc. (TRAX) - Zacks Investment Research
Two new option listings and one option delisting on May 11th - TipRanks
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
First Tracks Biotherapeutics, Inc. (TRAX) Cash From Operations (TTM) - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Net Income (TTM) - Zacks Investment Research
TRAX: First Tracks Biotherapeutics, Inc.Interactive Chart - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Eps Diluted (TTM) - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Ps Ratio (TTM) - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Debt Equity Ratio (Quarterly) - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Return On Equity (TTM) - Zacks Investment Research
First Tracks Biotherapeutics Stock Slides After Investors Move to Sell 10 Million Shares - Moomoo
Stocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences - Moomoo
TRAX Insider Trading (First Tracks Biotherapeutics Inc stock) - StockInvest.us
First Tracks Biotherapeutics Inc Stock Data and SignalsTRAX - StockInvest.us
According to a document submitted to the U.S. Securities and Exchange Commission, existing selling shareholders of First Tracks Biotherapeutics Inc may sell up to 10.5 million shares of the company’s common stock. - Bitget
First Tracks Biotherapeuticsselling stockholders may sell up to 10.5 shares of common stockSEC filing - marketscreener.com
First Tracks Biotherapeutics, Inc. (TRAX) Dividend Yield (TTM) - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Return On Assets (TTM) - Zacks Investment Research
First Tracks Biotherapeutics Inc (TRAX) 재무 분석
First Tracks Biotherapeutics Inc (TRAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):